Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00606827 |
Recruitment Status :
Completed
First Posted : February 5, 2008
Last Update Posted : May 8, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Contrast-Induced Nephropathy | Drug: Sodium Bicarbonate Drug: Isotonic Saline | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 500 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy in Patients Undergoing Coronary Angiography |
Study Start Date : | January 2005 |
Actual Study Completion Date : | March 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: A
Bicarbonate
|
Drug: Sodium Bicarbonate
Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure |
Active Comparator: B
Saline
|
Drug: Isotonic Saline
Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with creatinine clearance < 60 mL/min
Exclusion Criteria:
- contrast medium administration within the previous 10 days
- end-stage renal failure requiring dialysis
- refusal to give informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606827
Italy | |
Ospedale Misericordia e Dolce | |
Prato, Italy, 59100 |
Principal Investigator: | Mauro Maioli, MD | Cardiology Unit - Prato |
Responsible Party: | Mauro Maioli, MD, Ospedale Misericordia e Dolce |
ClinicalTrials.gov Identifier: | NCT00606827 |
Other Study ID Numbers: |
Prato0701 POCARD0701 |
First Posted: | February 5, 2008 Key Record Dates |
Last Update Posted: | May 8, 2012 |
Last Verified: | May 2012 |
Contrast-induced nephrophaty Contrast media Angiography Coronary percutaneous intervention |
Kidney Diseases Urologic Diseases |